Document 0089
 DOCN  M9460089
 TI    Presence of autologous neutralizing antibodies against cytomegalovirus
       (CMV) in serum of human immunodeficiency virus type 1-infected patients
       shedding CMV in saliva.
 DT    9408
 AU    Lucht E; Sundqvist VA; Linde A; Bratt G; Sandstrom E; Heimdahl A; Nord
       CE; Wahren B; Dept. of Virology, Swedish Institute for Infectious
       Disease; Control, Stockholm, Sweden.
 SO    J Infect Dis. 1994 May;169(5):1096-100. Unique Identifier : AIDSLINE
       MED/94223070
 AB    This study evaluated whether cytomegalovirus (CMV) neutralizing capacity
       affected shedding of CMV in saliva in human immunodeficiency virus type
       1 (HIV-1)-infected patients and mapped specific epitope reactivity of
       CMV IgG antibodies. Total CMV IgG titers were significantly higher in
       symptomatic than in asymptomatic HIV-1-infected patients or controls.
       All CMV-seropositive patients had neutralizing antibodies to CMV.
       Shedding of CMV in the saliva of AIDS patients occurs despite the
       presence of serum antibodies with a high capacity to neutralize
       autologous CMV isolates. The highest IgG reactivity against a CMV
       envelope protein (gp116), represented by a peptide, was found in
       patients with advanced HIV disease. In contrast, identical IgG
       reactivities against a peptide representing the CMV matrix protein were
       observed in healthy controls and HIV-1-infected persons.
 DE    Adult  Amino Acid Sequence  Antibodies, Viral/*BLOOD/IMMUNOLOGY
       Antigens, Viral/IMMUNOLOGY  Cytomegalovirus/*IMMUNOLOGY/ISOLATION &
       PURIF  Cytomegalovirus Infections/COMPLICATIONS/*IMMUNOLOGY/MICROBIOLOGY
       Human  HIV Infections/*COMPLICATIONS  Male  Middle Age  Molecular
       Sequence Data  Neutralization Tests  Saliva/*MICROBIOLOGY  Support,
       Non-U.S. Gov't  Virus Shedding  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).